Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.
about
Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contractionTolterodine use for symptoms of overactive bladder.The pharmacological treatment of urinary incontinence.Biochemical mechanisms of drug action: what does it take for success?Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.Tolterodine extended-release for overactive bladder.Evaluation of anti-hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain: a randomized placebo-controlled study.An overview of the clinical use of antimuscarinics in the treatment of overactive bladderPharmacological therapy of female urinary incontinence.The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy.Maximal functional electrical stimulation as a single treatment: is it cost-effective?Management of overactive bladder syndromeTolterodine for the treatment of overactive bladder.The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderlyUpdate on the management of overactive bladder: patient considerations and adherenceFesoterodine for the treatment of urinary incontinence and overactive bladder.Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction.Muscarinic acetylcholine receptors as effector sites for present and future therapeutic applications: focus on non-neural cholinergic systems.Combination of foot stimulation and tolterodine treatment eliminates bladder overactivity in cats.Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.Evaluation of fesoterodine fumarate for the treatment of an overactive bladder.Fesoterodine fumarate and the oxybutynin ring for the treatment of urinary incontinence in women.Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin.Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological TreatmentDose-ranging study of tolterodine in patients with detrusor hyperreflexia.A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.Systemic effects of intravesical atropine sulphate.Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies.Tolterodine: a safe and effective treatment for older patients with overactive bladder.Failure of tolterodine to treat clozapine-induced nocturnal enuresis.Long-acting formulation of a new muscarinic receptor antagonist for the treatment of overactive bladder.Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists.Synergistic effect of iontophoresis and chemical enhancers on transdermal permeation of tolterodine tartrate for the treatment of overactive bladder.Considering the prominent complaint as a guide in medical therapy for overactive bladder syndrome in women over 45 years.Inhibition of salivary secretion by tolterodine transdermal patch.Selective prescribing of spasmolytics.Antimuscarinic drugs for the treatment of female urinary incontinence.Evaluation of the effect of tolterodine on pupil diameter and anterior chamber parameters with the Pentacam.Muscarinic receptor agonists and antagonists
P2860
Q28578062-A8C143F8-8509-49F4-92BA-92118AD784DCQ30799852-B7F69112-B017-4F4C-A362-BB63521743FAQ33778812-A13BF8FF-C592-4366-963E-DD9D52C4E9DCQ34344862-B6E79D84-A5A7-4689-8A50-051C8D877C90Q34502903-56D151D8-6F9B-4B79-B6AB-B8D2D114E7F6Q34610640-5AFB2610-65A2-4F4E-B6B0-0A6BBFB4C2B6Q34647740-4A9500C1-0D34-47D0-9477-0A54B8AD2E0DQ35042575-02DE174B-E9C0-42FC-B278-6DFE44A505BAQ35697774-CA123083-1151-48CF-AEBD-37718A3233BBQ36428471-C6349EE0-7B7D-48D2-BDC1-3B44AE8C0DEFQ36799966-E483E7C9-B55D-41D3-A1CF-947E2CF40751Q36875672-BC5B7748-52FD-418A-98BA-D5BDA3E3BBEDQ37142090-C9129DEA-8D11-4303-AC41-20A41540BA4AQ37199946-1326F10B-CF03-41E9-AD2E-C3BD98B84F84Q37283704-94667CA4-3B40-4974-A8B1-DE34A0F95071Q37429813-09BD4435-B19F-4A79-A168-E957F589A3BCQ37484824-4F1525E9-6AE5-4E38-898F-6CDD36913F30Q37689776-A29893A3-04E0-4C2F-9397-6D880CD6361FQ37728633-A9B3280F-6343-4613-A0C7-02D58307CF78Q38032608-7CFCA44A-ADBF-436F-8517-697E89676231Q38160883-463FB179-C128-4EFE-9EF0-86C1E84CCE69Q38173919-17B94CD1-76B1-48C4-86FF-4C4029CBA813Q38590670-9A43A14E-C6C4-4061-8E58-A0581A14A91BQ38743428-6FC1B63E-485E-465D-AFE7-B3994BF8D9EEQ38860110-B4A00248-0AF8-48EB-A9A6-01596BCDC527Q40839606-3C792C8B-A167-4002-87BC-DB8638F0F417Q43109559-F8538418-B3EE-43CE-AD1E-D454524084FAQ43605815-B38850DF-357B-48A3-8065-A0741DA5D27DQ43617067-F71F1CA6-E545-4BE1-A488-DEE8DA6490E4Q43674684-2D3426F5-6C2C-402D-8FF7-7DED058F922EQ43695413-71A2EADD-F42F-4BD2-9501-E166C5EC15A4Q44023036-3BBA3E76-7285-41B5-9BD3-209382EB3FBFQ44036364-507F5E95-0B81-4A4E-B3FD-96BBEBB7DC2BQ44364551-BCC512F1-D572-4FE5-A80D-4391DC210C7AQ44426277-1B698108-FAEE-49F8-994B-B32048107B20Q48266047-39E85C6A-DBBC-48DC-B9F8-CEA2B4C0458BQ50135461-55D19A78-5450-4A83-81B1-62ECABC00DA1Q51817526-4BDACF9B-6E2E-4BCE-9C36-436CB64AB5F4Q53265532-0579B72A-D98B-403A-AB5B-DA43D1EA1D8BQ58856375-09AFF705-3C8D-4EF6-8495-033340FEFBAB
P2860
Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Tolterodine--a new bladder sel ...... macological and clinical data.
@en
type
label
Tolterodine--a new bladder sel ...... macological and clinical data.
@en
prefLabel
Tolterodine--a new bladder sel ...... macological and clinical data.
@en
P2093
P1433
P1476
Tolterodine--a new bladder sel ...... macological and clinical data.
@en
P2093
P304
P356
10.1016/S0024-3205(97)00057-X
P407
P577
1997-01-01T00:00:00Z